ALLMedicine™ Fallopian Tube Cancer Center

Jun 25th, 2022 - Preclinical evidence and early clinical trials have demonstrated the activity of SPL-108, a targeted agent that inhibits CD44 mediated induction of multidrug resistance specifically to paclitaxel and platinum agents. We conducted a phase I, open l...

Jun 24th, 2022 - Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines and human tumors implanted into immunocompromised...

Jun 23rd, 2022 - PRIMARY OBJECTIVE: I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to phy...

Jun 22nd, 2022 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or en...

Jun 22nd, 2022 - PRIMARY OBJECTIVES: I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by pr...

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Aug 24th, 2017 - Hereditary breast and ovarian cancer syndrome is an inherited cancer-susceptibility syndrome characterized by multiple family members with breast cancer, ovarian cancer, or both. Based on the contemporary understanding of the origins and managemen...

Jun 24th, 2022 - Background: Using both in vitro and in vivo assays we have shown that human monocytes primed with Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell lines and human tumors implanted into immunocompromised...

Jun 23rd, 2022 - PRIMARY OBJECTIVE: I. To assess the efficacy of the combinations durvalumab (MEDI4736) plus olaparib and cediranib, durvalumab (MEDI4736) plus cediranib, or olaparib and cediranib, as measured by progression-free survival (PFS), as compared to phy...

Jun 22nd, 2022 - This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or en...

Jun 22nd, 2022 - PRIMARY OBJECTIVES: I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by pr...

Jun 15th, 2022 - This cross-sectional, noninterventional, multicentre, epidemiological, observational study is designed to determine the prevalence of HRD in patients with newly diagnosed high-grade serous or endometrioid ovarian, primary peritoneal, and/or fallop...

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Mar 19th, 2022 - Single-agent olaparib (Lynparza) generated similar overall survival (OS) compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis o...

Mar 17th, 2022 - At a median follow-up of 3.5 years, adjuvant olaparib (Lynparza) significantly improved overall survival (OS) vs placebo in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who received prior chemotherapy before or...

Nov 17th, 2021 - The investigative agent SL-172154 (SIRPα-Fc-CD40L) was found to be well tolerated, with no dose-limiting toxicities (DLTs) observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial pre...

Oct 6th, 2021 - Matthew Powell, MD Although enthusiasm remains for developing immunotherapies for patients with ovarian cancer, phase II studies evaluating the treatment’s efficacy in the recurrent population have been disappointing thus far, explained Matthew P...